1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Encision's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 132.95%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Encision's 1-Year ROIIC % or its related term are showing as below:
ECIA's 1-Year ROIIC % is ranked better than 85.35% of 833
companies
in the Medical Devices & Instruments industry
Industry Median: 3.67
vs ECIA: 132.95
Encision 1-Year ROIIC % Historical Data
The historical data trend for Encision's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Encision's 1-Year ROIIC %
For the Medical Instruments & Supplies subindustry, Encision's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encision's 1-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encision's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Encision's 1-Year ROIIC % falls into.
Encision 1-Year ROIIC % Calculation
Encision's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -0.391 (Dec. 2023) - -0.625 (Dec. 2022) )
/
( 3.756 (Dec. 2023) - 3.58 (Dec. 2022) )
=
0.234
/
0.176
=
132.95%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Encision (OTCPK:ECIA) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Encision 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Encision's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ECIA has been successfully added to your 